TREATING FLUID OVERLOAD
IN CHF & CKD PATIENTS
WITH A NON-INVASIVE
DRUG-FREE TECHNOLOGY

Discover the only non-invasive technology that offers natural fluid removal which bypasses the renal system and can be operated by the patient at home

About AquaPass

Persistent volume overload and congestion are the most common problems in renal and heart failure. In the US alone, every year one milllion patients are hospitalized. The accumulation of fluids can be life-threatening and require advanced care in the hospital or urgent care facilities. 

AquaPass addresses heart and renal failure’s biggest challenge – the management of fluid overload. 

The AquaPass System is a non-invasive, renal-independent system intended to manage fluid overload in patients requiring medical intervention. With confirmed performance in various clinical trials, AquaPass’s mission is to transform the treatment paradigm of fluid overload using an innovative approach that is safer and more effective.

The AquaPass System

The AquaPass system is the first noninvasive, drug-free, fluid overload treatment solution for chronic heart failure (CHF) and end-stage renal disease (ESRD).

Granted FDA breakthrough technology, the system utilizes a patented wearable suit and control unit to activate the Eccrine Glands inducing natural perspiration at 200 mL/Hr.

The suit efficiently distributes warm air, and instantaneously evaporates the removed fluids from the skin cooling the cutaneous circulation keeping normal body core temperature, and the patient dry and comfortable. The control unit ensures continuous monitoring for patient’s safety.

Clinical studies demonstrate its safety at home and in hospital use, reporting 0% adverse events, side effects, or mortality during 2 months of treatments and significant improvement in congestion status and quality of life.

Clinical Evidence

The AquaPass system is currently under investigation for chronic heart failure, kidney disease, and end-stage renal disease, with all study endpoints successfully achieved

Clinical Meaningful

Fluid Removal
of >850ml per AquaPass treatment session

High Safety Profile

No hospitalizations for fluid overload, no worsening renal function, no side effects

Patient Compliance

Comfortable, easy to operate and preferred over IV Diuretics

Clinical Benefits

Marked reduction in
NT-ProBNP and diuretics with improved congestion score

Clinical Trials Results

Clinical trials demonstrate that the use of the AquaPass system in fluid overloaded patients (CHF, ESRD) is safe and clinically meaningful

0%

180 Day Mortality &
30 Day HF-Readmissions

>850 mL

Average Fluid Removal
Per 4-Hour Treatment

46%

Improvement in Quality of Life (KCCQ-12 Questionnaire)

30%

Reduction in Diuretics Dosages

Aronson et al. AQP-009

Effect on Ultrafiltration in End Stage Renal Disease

Clinical trial shows AquaPass treatment at home markedly reduced ultrafiltration rates, potentially lowering mortality risk

There is a consensus that mortality rate increases with the elevation in ultrafiltration rates, and it is difficult to achieve in many patients under current medical treatment.

AquaPass treatment at home, over the weekend, demonstrated marked reduction in ultrafiltration rates in the same patients, potentially lowering their mortality risk.

Assimon, et al. Ultrafiltration Rate and Mortality in Maintenance Hemodialysis Patients. Am J Kidney Dis. 2016;68(6):911-922.

Hear from One of Our Patients

Our Management

Yaacov Nitzan
Founder & CTO

Or Inbar
Head of R&D

Ofer Hornick, MD
VP Regulatory Affairs

Rotem Katzenellenbogen
CCO

Board of Directors

Yaacov Nitzan
Founder & CTO

Alon Maor
Chairman, Lifescience investor, BRM

Moshe Mizrahy
MedTech Entrepreneur 

Adi Gur

Adi Gur
CEO, Arbelon Holdings

Tovy Sivan, B.Sc., MBA

Tovy Sivan
MedTech Entrepreneur 

Scientific Advisory Board

William T. Abraham, MD
Ohio State University, USA

Daniel Burkhoff, MD
Cardiovascular Research Foundation
New York, USA

Doron Aronson, MD
Dir. Inpatient Cardiology Unit, Rambam Medical Center, Israel

Ron Wald, MD
Nephrologist, St. Michael’s Hospital Toronto, Canada

Ran Kornowski, MD
Dir. Cardiology Unit, Rabin Medical Center, Israel

Gil Chernin, MD
Nephrologist. Head of Unit, Kaplan Medical Center, Israel

Dan Bensimhson, MD
Advanced Heart Failure & Mechanical Circulatory
Support Program, Cone Health, USA

Tina Ivovic
Healthcare Economics & Reimbursement Expert

News & Events

Successful completion of another study in ADHF with Fluid Overload

January 22, 2024

Aquapass

The FDA has granted us another Breakthrough Device Designation, this time for ESRD

February 7, 2024

Aquapass

The FDA has granted us Breakthrough Device Designation for CHF Patients

November 30, 2023

Aquapass

Successful completion of First-In-Human study for Fluid Removal in Hemodialysis Patients

December 30, 2023

Aquapass

Microclimate suit helps heart and renal patients with fluid buildup

American Technion society

February 28, 2023

Aquapass

No sweat: Aquapass Microclimate Suit enters FDA pre-submission application stage

Bio world

March 8, 2023

Aquapass

The FDA has granted
us designation as a
Breakthrough Device

December, 2022

Aquapass

Presentation at the
CSI Focus D-HF
conference,
Frankfurt

December 9, 2022
Aquapass

Israeli invention-

A wearable suit designed for fluids disposal through the skin in heart failure patients.

October 19, 2022

AquaPass
Medical Wins
“Most promising
early-stage
startup” at
TCT 2021

November 6, 2021

AquaPass Medical Wins “Most promising early-stage startup” at TCT 2021

AquaPass
Successfully
Completes Proof
of Concept Study

October 10, 2021

Aquapass